Co-Target(s) Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T20761 | Target Info | |||
Target Name | Vascular endothelial growth factor A (VEGFA) | ||||
Synonyms |
Vascular permeability factor; VPF; VEGF-A; VEGF
Click to Show/Hide
|
||||
Target Type | Successful Target | ||||
Gene Name | VEGFA | ||||
Biochemical Class | Growth factor | ||||
UniProt ID |
Co-Targets of This Target | Top | |||||
---|---|---|---|---|---|---|
Co-Target Name | Farnesoid X-activated receptor (FXR) | Successful Target | ||||
UniProt ID | NR1H4_HUMAN | |||||
Gene Name | NR1H4 | |||||
Synonyms |
Retinoid X receptor-interacting protein 14; RXR-interacting protein 14; RIP14; Nuclear receptor subfamily 1 group H member 4; HRR1; Farnesol receptor HRR-1; FXR; Bile acid receptor; BAR
Click to Show/Hide
|
|||||
Representative Drug(s) | Bevacizumab + Trastuzumab | Drug Info | IC50 = 18.3 nM | [1] | ||
Co-Target Name | Indoleamine 2,3-dioxygenase 1 (IDO1) | Successful Target | ||||
UniProt ID | I23O1_HUMAN | |||||
Gene Name | IDO1 | |||||
Synonyms |
Indoleamine-pyrrole 2,3-dioxygenase; INDO; IDO-1; IDO
Click to Show/Hide
|
|||||
Representative Drug(s) | Avastin+/-Tarceva | Drug Info | IC50 = 1000 nM | [2] | ||
Co-Target Name | G-protein coupled bile acid receptor 1 (GPBAR1) | Clinical trial Target | ||||
UniProt ID | GPBAR_HUMAN | |||||
Gene Name | GPBAR1 | |||||
Synonyms |
hGPCR19; hBG37; TGR5; Membrane-type receptor for bile acids; M-BAR; G-protein coupled receptor GPCR19; BG37
Click to Show/Hide
|
|||||
Representative Drug(s) | Bevacizumab + Trastuzumab | Drug Info | EC50 = 580 nM | [3] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor. Bioorg Med Chem. 2014 Jun 1;22(11):2919-38. | ||||
REF 2 | Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18. | ||||
REF 3 | Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem. 2008 Mar 27;51(6):1831-41. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.